NCT04772053View on ClinicalTrials.gov

Molecular Disease Characterization Initiative (MDCI)

PHASE2TerminatedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

May 25, 2021

Primary Completion Date

November 15, 2022

Study Completion Date

November 15, 2022

Conditions

Lung Cancer, Non-Small CellNeoplasms

Interventions

PROCEDURE

Tumor biopsy

Archived or fresh tumor biopsy samples will be collected.

Trial Locations (2)

28050

GSK Investigational Site, Madrid

37203

GSK Investigational Site, Nashville

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY